Straight Shot with Dr. Clete Barrick

ECO 2026: 5 Studies That Will Change How You Use GLP-1s

Twelve thousand researchers. Hundreds of presentations. Five studies that matter. Dr. Clete Barrick breaks down the most important GLP-1 research presented at the European Congress on Obesity 2026 in Istanbul, and what each finding means for patients on Ozempic, Wegovy, Mounjaro, and Zepbound right now. He covers the new higher-dose Wegovy data (7.2 mg), the maintenance dosing trial Zepbound patients have been waiting for, what happens when you switch from an injection to an oral pill, the real-world data showing half of patients quit before they get the benefit, and the Viking Therapeutics oral pill that may compete with injectable tirzepatide by 2028. Each study gets the same three-beat treatment: what happened, why you should care, and what you should do about it. In this episode: * STEP UP: Wegovy 7.2 mg delivers 20.7% weight loss, with responders hitting 27.7% * Medicare BRIDGE program adding Wegovy 7.2 on July 1 * SURMOUNT-MAINTAIN: 5 mg tirzepatide as a legitimate maintenance dose * Why the dose ladder mental model is wrong * ATTAIN-MAINTAIN: Switching from Wegovy to oral orforglipron (Foundayo) vs. switching from Zepbound * Why the GIP receptor matters when you change medications * Wilding real-world data: 50% discontinuation, dose-dependent metabolic benefits * The most important variable in GLP-1 treatment (it's not which drug) * Viking VK2735: 12.2% loss in 13 weeks from an oral dual agonist * What the pill landscape looks like in 2028 New episodes weekly. Subscribe and visit barrickhealth.com for physician-led GLP-1 care. Everything discussed in this episode is education, not medical advice for your specific situation. Talk to your prescriber before making changes to your treatment. LINKS barrickhealth.com https://www.youtube.com/@BarrickHealth [https://www.youtube.com/@BarrickHealth] TAGS/KEYWORDS (Paste into Buzzsprout tags field, comma-separated) ECO 2026, European Congress on Obesity, STEP UP trial, Wegovy 7.2, SURMOUNT-MAINTAIN, tirzepatide maintenance dose, Zepbound maintenance, ATTAIN-MAINTAIN, orforglipron, Foundayo, Viking VK2735, VENTURE-2, Wilding real-world data, GLP-1 discontinuation, GLP-1 news, oral GLP-1 pill, Medicare BRIDGE program, semaglutide vs tirzepatide, dual agonist, GIP receptor, obesity medicine, Dr. Clete Barrick, Straight Shot podcast REFERENCES CITED * STEP UP trial. Higher-dose semaglutide 7.2 mg for obesity. Presented at European Congress on Obesity (ECO) 2026, Istanbul. Novo Nordisk. * Wadden TA, et al. Tirzepatide for maintenance of weight reduction (SURMOUNT-MAINTAIN). The Lancet. 2026. * ATTAIN-MAINTAIN trial. Transition from injectable semaglutide or tirzepatide to oral orforglipron. Presented at ECO 2026, Istanbul. Eli Lilly. * Wilding JPH, et al. Real-world discontinuation and metabolic outcomes of GLP-1 receptor agonists in 90,000 patients (UK/EU). Presented at ECO 2026, Istanbul. * VENTURE-2 trial. Phase 2 results for oral dual GLP-1/GIP agonist VK2735. Presented at ECO 2026, Istanbul. Viking Therapeutics. * Medicare BRIDGE Program formulary update, effective July 1, 2026.

Foundayo vs. Oral Wegovy: Which GLP-1 Pill Should You Actually Take?

There are now two FDA-approved GLP-1 pills for weight loss, and they are not the same drug. Dr. Clete Barrick (board-certified in internal medicine and obesity medicine) breaks down the side-by-side: the chemistry, the dosing rules, the weight loss data, the side effects, the cost, and which patient profile fits each pill. What you'll learn: - Why Foundayo (orforglipron) and oral Wegovy (semaglutide 25 mg) are pharmacologically different drugs, not just two brands of the same thing - The morning ritual oral Wegovy requires and why pharmacokinetic studies say you can't cheat it - Trial weight loss numbers from ATTAIN-1 (Foundayo) and OASIS 4 (oral Wegovy) and what the 1.2-point gap actually means in real life - The side effect paradox: lower nausea on Foundayo but higher discontinuation at the top dose - May 2026 self-pay and insured pricing through LillyDirect and NovoCare - The patient profiles where each pill is the right answer, and the case where a needle is still better than a pill Timestamps: 0:00 — Opening 0:45 — Welcome to Straight Shot 1:00 — Why this matters now 2:30 — Shot 1: The chemistry 4:45 — Shot 2: How you take each pill 7:00 — Shot 3: How much weight comes off 9:15 — Shot 4: The side effect paradox 11:30 — GLP-1 Bible pre-order 12:00 — Shot 5: What you'll actually pay 13:00 — The Straight Shot 14:30 — Wrap & subscribe Studies and sources referenced: - Wharton S, Aronne LJ, Stefanski A, et al. Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1). NEJM. 2025;393(18):1796-1806. - Wharton S, Lingvay I, Bogdanski P, et al. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity (OASIS 4). NEJM. 2025;393(11):1077-1087. - Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). NEJM. 2021;384(11):989-1002. - Buckley ST et al. Transcellular stomach absorption of a derivatized GLP-1 receptor agonist. Sci Transl Med. 2018;10(467):eaar7047. - Granhall C et al. Safety and pharmacokinetics of single and multiple ascending doses of oral semaglutide. Clin Pharmacokinet. 2019;58(6):781-791. - Foundayo (orforglipron) Prescribing Information. Eli Lilly. April 2026. - Wegovy (semaglutide tablets) Prescribing Information. Novo Nordisk. December 2025. - Eli Lilly. ATTAIN-MAINTAIN press release, December 18, 2025. - LillyDirect Foundayo pricing, April 2026. - NovoCare Wegovy pricing, April 2026. Resources: - Pre-order The GLP-1 Bible: barrickhealth.com - Book a 1-on-1 consult with Dr. Barrick: barrickhealth.com - YouTube: @BarrickHealth - Reddit: u/CleteBarrickMD Disclaimer: This episode is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting, stopping, or changing any medication.

The "Hidden" GLP-1 Side Effects Study: What Every Headline Got Wrong

A new study in Nature Health used AI to scan over 400,000 Reddit posts from 67,000 GLP-1 users and uncovered side effects that aren't on the label. Fox News, CNN, and Medscape ran the same headline: "hidden side effects doctors are missing." Dr. Clete Barrick, board-certified in internal medicine and obesity medicine, prescribes these medications every day and takes tirzepatide himself. In this episode, he walks through what the University of Pennsylvania researchers actually found, why the methodology matters, and where every headline got it wrong. You'll hear the truth about the 13% psychiatric symptom finding, why menstrual changes and cold sensitivity aren't "hidden" at all, and the real story buried under the clickbait: the system for catching side effects is broken. Includes counter-data from The Lancet Psychiatry and Nature Medicine showing GLP-1s are associated with lower mental health risk, not higher. If you want a physician who actually monitors all of this, book a free consult at barrickhealth.com. Subscribe for weekly evidence-based GLP-1 content from a doctor who's been on the medication. YouTube: youtube.com/@BarrickHealth

Semaglutide vs. Tirzepatide: A Doctor's Honest Comparison

Semaglutide or tirzepatide? Ozempic or Mounjaro? It's the most asked question in GLP-1 medicine, and Dr. Clete Barrick has prescribed both to over 5,000 patients. In this episode, he covers the real differences between single and dual agonist medications, the head-to-head SURMOUNT-5 trial results, side effect profiles (including the birth control interaction most providers miss), who actually does better on which medication, and why the best GLP-1 is the one you can afford to stay on. He also addresses compounding costs, why semaglutide is sometimes the smarter pick despite tirzepatide's stronger averages, the oral Wegovy option for patients with needle phobia, and the fear-mongering around FDA regulatory moves that's driving patients to make bad decisions. In this episode: * Single vs. dual agonist: what the mechanism difference actually means * SURMOUNT-5 and the 2026 Bernardi meta-analysis (28 trials, 34,000 patients) * Why averages hide a massive spread in individual responses * GI side effects compared (and why tirzepatide is often better tolerated) * The birth control absorption warning (59% reduction with tirzepatide) * Autoimmune conditions, migraines, and PCOS: which medication has the edge * Compounding costs: semaglutide vs. tirzepatide pricing reality * The sledgehammer vs. Michelangelo analogy * Why you shouldn't switch medications based on social media fear New episodes weekly. Subscribe and visit barrickhealth.com for physician-led GLP-1 care. Everything discussed in this episode is education, not medical advice for your specific situation. Talk to your prescriber before making changes to your treatment. LINKS: barrickhealth.com https://www.youtube.com/@BarrickHealth [https://www.youtube.com/@BarrickHealth] REFERENCES CITED: * Jastreboff AM, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5). N Engl J Med. 2025. * Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002. * Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216. * Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT). N Engl J Med. 2023;389:2221-2232. * Bernardi S, et al. Network meta-analysis of tirzepatide vs semaglutide (28 RCTs, 34,367 patients). J Diabetes. 2026. * Mounjaro prescribing information: oral contraceptive absorption interaction data.

How GLP-1s Actually Work (in Plain English)

Your body already makes GLP-1 every time you eat. The problem? Natural GLP-1 lasts about two minutes before an enzyme destroys it. Semaglutide and tirzepatide are engineered to do the same job, just louder and longer. Dr. Clete Barrick breaks down how these medications work at three job sites: your pancreas, your stomach, and (most importantly) your brain. He explains the difference between homeostatic hunger and hedonic hunger, why GLP-1s quiet "food noise" through the brain's reward circuit, and why the "you only lose weight because you feel sick" myth is flat wrong. In this episode: * GLP-1: the hormone you already make * Three job sites: pancreas, stomach, brain * Homeostatic vs. hedonic hunger (the car wash sign analogy) * Why less than 1% of weight loss comes from nausea * Semaglutide vs. tirzepatide: what's different * What GLP-1s don't do * The Straight Shot: you are not cheating No biochemistry degree required. Just the science you need to understand what's happening when you take your shot. New episodes weekly. Subscribe and visit barrickhealth.com for physician-led weight loss care.